Patents by Inventor Christoph Patsch
Christoph Patsch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240085402Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: ApplicationFiled: October 20, 2023Publication date: March 14, 2024Inventors: Veronica COSTA, Maj HEDTJÄRN, Marius HOENER, Ravi JAGASIA, Mads Aaboe JENSEN, Christoph PATSCH, Lykke PEDERSEN, Søren Vestergaard RASMUSSEN
-
Publication number: 20240066060Abstract: This disclosure provides compositions and methods for the treatment of inherited metabolic disorders in a subject. Provided herein are compositions and methods to treat Lysosomal Storage Diseases (LSD) in a subject using myeloid cells.Type: ApplicationFiled: April 27, 2023Publication date: February 29, 2024Inventors: Ibrahim John DOMIAN, Panagiotis DOUVARAS, Christoph PATSCH, Chew-Li SOH, Stephanie A. FISHER, Maya SRINIVAS, Jing WANG, Carlos PALADINI, Ashley E. LEPACK
-
Patent number: 11852627Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: GrantFiled: January 21, 2022Date of Patent: December 26, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Publication number: 20230296587Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD1091B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: ApplicationFiled: February 22, 2023Publication date: September 21, 2023Inventors: Veronica COSTA, Maj HEDTJÄRN, Marius HOENER, Ravi JAGASIA, Mads Aaboe JENSEN, Christoph PATSCH, Lykke PEDERSEN, Søren Vestergaard RASMUSSEN
-
Publication number: 20220298490Abstract: This application relates to methods for generating monocytic progenitor cells and their differentiation into macrophages and microglia as well as to large scale cell cultures for producing monocytic progenitor cells.Type: ApplicationFiled: November 5, 2021Publication date: September 22, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Nadine DAHM, Simon GUTBIER, Christoph PATSCH
-
Publication number: 20220146496Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: ApplicationFiled: January 21, 2022Publication date: May 12, 2022Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Patent number: 11320421Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: GrantFiled: July 20, 2020Date of Patent: May 3, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Publication number: 20200348286Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: ApplicationFiled: July 20, 2020Publication date: November 5, 2020Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Patent number: 10739332Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: GrantFiled: April 18, 2019Date of Patent: August 11, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Patent number: 10718753Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: GrantFiled: October 24, 2019Date of Patent: July 21, 2020Assignee: Hoffman-La Roche Inc.Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Publication number: 20200182861Abstract: This application relates to a method for differentiating pluripotent stem cells (PSCs) into vascular bed cells. Moreover this application relates to a method for differentiating human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into vascular bed cells based on linked steps of chemically defined medium inductions.Type: ApplicationFiled: September 5, 2019Publication date: June 11, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Klaus Christensen, Martin Graf, Roberto Iacone, Christoph Patsch, Eva Christina Thoma
-
Publication number: 20200057052Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: ApplicationFiled: October 24, 2019Publication date: February 20, 2020Inventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Patent number: 10494633Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: GrantFiled: November 14, 2016Date of Patent: December 3, 2019Assignee: Roche Innovation Center Copenhagen A/SInventors: Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Publication number: 20190310244Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: ApplicationFiled: April 18, 2019Publication date: October 10, 2019Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Publication number: 20190154664Abstract: This patent application relates to a method for determining the in vitro efficacy profile of a drug candidate using standardized cell cultures of uniformly distributed differentiated neural cells (NCs) from at least two primate species, wherein the differentiated NC cultures are qualified for high throughput screening based on a dissociation and reseeding step performed on the differentiated NCs. The method includes differentiating human and/or non-human primate neuronal precursor cells (NPCs) to neuronal cells (NCs) followed by dissociating the differentiated NCs from its support and reseeding the differentiated NCs in a high-throughput cell culture format resulting in robust cultures suitable for high-throughput drug screening assays, in particular to screen antisense oligonucleotides.Type: ApplicationFiled: May 11, 2018Publication date: May 23, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Carlo CUSULIN, Veronica COSTA, Marius HOENER, Christoph PATSCH, Eva Christina THOMA
-
Publication number: 20190144824Abstract: This patent application relates to a method to generate standardized and robust neuronal cell culture assays from primate species, for example suitable for high-throughput screening of drug candidates. The method includes differentiating human and/or non-human primate neuronal precursor cells (NPCs) to neuronal cells (NCs) and producing uniform NC cultures based on a dissociation and reseeding step performed on the differentiated NCs resulting in robust cultures suitable for high-throughput drug screening assays, in particular to screen antisense oligonucleotides.Type: ApplicationFiled: May 11, 2018Publication date: May 16, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Carlo CUSULIN, Veronica COSTA, Marius HOENER, Christoph PATSCH, Eva Christina THOMA
-
Patent number: 10138468Abstract: This application relates to a method for differentiating pluripotent stem cells (PSCs) into multi-competent renal precursor cells expressing Six2. These renal precursor cells are able to differentiate into fully functional and fully differentiated podocytes. Moreover this application relates to a method for differentiating human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into defined renal precursor cells expressing Six2 and podocytes based on linked steps of chemically defined medium inductions.Type: GrantFiled: January 29, 2016Date of Patent: November 27, 2018Assignee: Hoffmann-La Roche Inc.Inventors: Jacques Bailly, Osele Ciampi, Martin Graf, Roberto Iacone, Christoph Patsch
-
Publication number: 20170191064Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Type: ApplicationFiled: November 14, 2016Publication date: July 6, 2017Inventors: Veronica Costa, Maj HEDTJÄRN, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
-
Publication number: 20160145578Abstract: This application relates to a method for differentiating pluripotent stem cells (PSCs) into multi-competent renal precursor cells expressing Six2. These renal precursor cells are able to differentiate into fully functional and fully differentiated podocytes. Moreover this application relates to a method for differentiating human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into defined renal precursor cells expressing Six2 and podocytes based on linked steps of chemically defined medium inductions.Type: ApplicationFiled: January 29, 2016Publication date: May 26, 2016Applicant: Hoffmann-La Roche Inc.Inventors: Jacques Bailly, Osele Ciampi, Martin Graf, Roberto Iacone, Christoph Patsch
-
Publication number: 20150017674Abstract: This application relates to a method for differentiating pluripotent stem cells (PSCs) into vascular bed cells. Moreover this application relates to a method for differentiating human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into vascular bed cells based on linked steps of chemically defined medium inductions.Type: ApplicationFiled: December 9, 2013Publication date: January 15, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Klaus Christensen, Martin Graf, Roberto Iacone, Christoph Patsch, Eva Christina Thoma